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Abstract:  We  aimed  to  evaluate  whether  the  enhancement  of  the  liver  accumulation 
and  anti-inflammatory  activity  of  dexamethasone  acetate  (DXMA)  could  be  achieved  by 
incorporating it into nanostructured lipid carrier (NLCs). DXMA-NLCs were prepared using 
a film dispersion-ultrasonication method and characterized in terms of particle size, PDI, zeta 
potential, differential scanning calorimetry, drug loading capacity, encapsulation efficiency, 
and in vitro release. The biodistribution and pharmacokinetics of DXMA-NLCs in mice were 
significantly different from those of the DXMA solution (DXMA-sol). The peak concentration 
of  DXMA-NLCs  was  obtained  half  an  hour  after  intravenous  administration.  More  than 
55.62% of the total administrated dose was present in the liver. An increase of 2.57 fold in the 
area under the curve was achieved when compared with that of DXMA-sol. DXMA-NLCs 
exhibited a significant anti-inflammatory and hepatoprotective effect on carrageenan-induced 
rats and carbon tetrachloride-induced mice compared with DXMA-sol. However, the effect 
was not in proportion to the dosage. The intermediate and low dosages presented better effects 
than DXMA-sol. All results indicate that NLCs, as a novel carrier for DXMA, has potential for 
the treatment of liver diseases, increasing the cure efficiency and decreasing the side effects 
on other tissues.
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Inflammatory processes are involved in a large number of liver diseases and may 
lead to liver fibrosis and cirrhosis.1 Dexamethasone acetate (DXMA) is a synthesized 
glucocorticoid, which has been used as an anti-inflammatory drug in the treatment of 
chronic active hepatitis for the prevention of liver fibrosis.2 Although DXMA enhances 
hepatocyte viability and improves the expression of liver-specific genes in liver diseases, 
the response rates obtained from a series of recent clinical trials were poor, which 
can be explained by the following factors. Firstly, DXMA has poor water solubility 
and is almost insoluble in most physiologically compatible and pharmaceutically 
acceptable solvents, both of which limit its clinic applications.3 Secondly, DXMA 
does not act specifically on liver cells, and long term use of large doses may lead to 
many side effects, such as osteoporosis, an increased risk of infections, and Cushing’s 
syndrome, especially during chronic use.1 To overcome these problems, micro/
nanoparticulate delivery systems were utilized for the encapsulation of DXMA. 
Polytrimethylene carbonate and PLGA were used to improve the aqueous solubility 
and in vitro release of dexamethasone, but in vivo results were not reported.4–6International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
488
Wang et al
Particulate carriers usually accumulate in the liver 
by passive targeting upon parenteral administration.7 
Oxymatrine and 5-fluorouracil prodrug were incorporated 
in solid lipid nanoparticles (SLNs) and showed higher liver 
targeting efficacy compared with free drug.8,9 Nanostructured 
lipid carriers (NLCs) are the second generation of 
lipid nanoparticles, composed of a binary mixture of solid 
lipid and a spatially different liquid lipid as a carrier.6 Though 
the major advantages of NLCs include increased drug loading 
capacity and decreased drug expulsion compared with SLNs, 
to date, very few researchers have systematically explored 
the in vivo liver targeting of NLCs.
Recently, we developed liver targeting DXMA-NLCs 
by a film dispersion-ultrasonication method. In this study 
we aimed to evaluate whether the enhancement of the 
liver accumulation and anti-inflammatory activity of 
DXMA could be obtained by incorporated into NLCs. The 
biodistribution and pharmacokinetics of DXMA-NLCs 
were studied in normal mice and the therapeutic efficacy 
was investigated on carrageenan-induced rats and carbon 
tetrachloride-induced mice for the first time.
Materials and methods
chemicals and animals
DXMA was supplied by Tianyao Pharmaceutical Co. Ltd. 
(Tianjin, P.R.C.). Pluronic 188 (F68) and carrageenan were 
purchased from Sigma (St. Louis, MO, USA). Purified egg 
yolk lecithin (Lipoid E80) was obtained from LIPOID GMBH 
(Ludwigshafen, Germany). Soybean oil for parenteral use 
was supplied by Beiya Co. Ltd. (Tieling, P.R.C.) and tween 
80 from Bodi Chemicals Co. Ltd. (Tianjin, P.R.C.). Carbon 
tetrachloride (CCl4) was obtained from Kelong Chemicals 
Co. Ltd. (Chengdu, P.R.C.). Alanine aminotransferase, aspar-
tate aminotransferase, and alkaline phosphatase assay kits 
were purchased from Jiancheng Institute of Biotechnology 
(Nanjing, P.R.C.). A hydroxyproline assay kit was supplied 
by Bei Fang Wei Ye Co. Ltd. (Beijing, P.R.C.). All other 
chemicals were of analytical grade.
Kunming mice weighing between 18 and 22 g and Wistar 
rats weighing between 180 and 200 g were purchased from the 
Laboratory Animal Center of Sichuan University (Chengdu, 
P.R.C.).
Preparation of DXMA loaded NLcs
DXMA-NLCs were prepared by a film dispersion-
  ultrasonication method.10 Briefly, 15 mg of DXMA, 100 mg 
of Soybean oil (SO), and 100 mg of lecithin were dissolved in 
CH2Cl2. The solution was evaporated under reduced pressure 
to remove the solvent and form a thin layer of uniform film on 
the wall of a round-bottom flask. A total of 20 mL of aqueous 
phase containing surfactants F68(2%, w/v) and tween 
80(2%, w/v) was added to disperse the film. The mixture 
was then further dispersed ultrasonically for 5 minutes to 
obtain NLCs. DXMA-containing NLCs were then purified 
by filtration through a cellulose acetate membrane (0.8 µm) 
to eliminate drug crystals. After purification, the NLC 
dispersions were freeze-dried for storage with mannitose as 
the cryoprotector.
characterization of NLcs
The NLCs were characterized for their size, PDI, and zeta 
potential with a Malvern Zatasize NanoZS90 (Malvern 
Instruments Ltd., Malvern, UK). Differential scanning 
calorimetry (DSC) and  31P Nuclear Magnetic Resonance 
Spectroscopy (31P  NMR)  of  blank  NLCs,  DXMA, 
DXMA-NLCs, and a physical mixture of blank NLCs and 
DXMA (the same ratio as that of the DXMA-NLCs) were 
performed on a DSC 204 (NETZSCH, Selb, Germany) and 
an AV300 spectrometer (Bruker, Rheinstetten, Germany).
The drug loading capacity (LC%) and encapsulation 
efficiency (EE%) were determined in triplicate by HPLC. 
The freeze-dried samples were redispersed in a solution of 
methanol/water (7:3, v/v) and sonicated. Subsequently, the 
suspensions were centrifuged (11,100 × g, 5 minutes), and 
the supernatant was assayed by HPLC for the total amount 
of DXMA in lipid nanoparticles. The amount of DXMA 
contained in the NLCs was determined by resuspending the 
same freeze-dried samples in 1 mL water, adding 0.2 mL 
NaCl solution (0.9%) to salt out the unincorporated drugs and 
centrifuging (18,000 × g, 20 minutes). The upper suspensions 
were then added to methanol, sonicated, and centrifuged 
(11,100 × g, 5 minutes). Finally, the supernatant was tested 
by the same HPLC method for the determination of DXMA 
entrapped within the NLCs. The HPLC system consisted of 
an Alltech Model 426 HPLC Pump, an Alltech UVIS-201 
Absorbance Detector, and an Allchrom plus Client/Server 
data operator (Alltech International, Inc., Virginia, USA). 
The mobile phase contained a ratio of methanol: water of 
70:30. A Shimpack CLC-ODS C18 column (150 × 4.6 mm, 
5 µm, Dikma Diamonsil®, Dikma Inc., Shanghai, P.R.C) was 
eluted at a flow rate of 1.0 mL/min. The eluate was monitored 
at 30°C and DXMA was assayed at a wavelength of 240 nm. 
EE% and LC% of DXMA loaded NLCs were calculated as 
given below:
EE% = amount of DXMA encapsulated in NLC/total 
amount of DXMA in lipid nanoparticles × 100%.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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LC% = amount of DXMA encapsulated in NLC/total 
amount of NLC × 100%.
In vitro release study of DXMA-NLcs
The Visking bag method was used to investigate the in vitro 
release of DXMA loaded NLCs. Briefly, DXMA-NLCs were 
resuspended in 5 mL water at a concentration of 100 µg/mL, 
transferred into the dialysis bag and dialyzed against 45 mL 
phosphate buffer (pH 7.4, containing 0.03 wt% SDS). 
During dialysis, a constant temperature shaker (Shenzhen 
Worldwide Industry, Co. Ltd., Shenzhen, P.R.C) was used, 
thermostatted at 37 ± 1°C and mechanically shaken at a 
suitable rotation speed.
At designated time intervals, 1 mL samples of the dialysis 
medium was taken for HPLC measurement of DXMA and 
the same volume of fresh medium was added. The release 
experiments were performed in triplicate.
In vivo biodistribution  
and pharmacokinetic studies  
of DXMA-NLcs
The Sichuan University animal ethical experimentation 
committee approved all procedures of the in vivo studies, 
according to the requirements of the National Act on the use 
of experimental animals (P.R.C.). Kunming mice received a 
single intravenous (iv) injection of DXMA-NLCs or DXMA 
solution at a DXMA equivalent dose of 10 mg/kg. The mice 
were sacrificed at 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 12 hours 
after iv administration. Blood samples were collected from 
the orbit venous plexus and plasma samples were obtained 
by centrifugation at 5,000 × g for 10 minutes. The tissues, 
including heart, lung, liver, spleen, and kidney were harvested 
and accurately weighed and homogenized. Plasma and tis-
sue samples within the same group were pooled together for 
further analysis (n = 5).
The DXMA concentrations in the plasma or tissues were 
determined by an HPLC assay. The extraction procedure was as 
follows. Plasma or tissue homogenates (0.5 mL) were mixed with 
0.1 mL methyltestosterone solution (8.66 µg/mL) as the internal 
standard and 0.2 mL phosphate buffer (pH = 2.0). The mixture 
was vortexed with 3 mL acetoacetate and then centrifuged 
(5,900 × g, 10 minutes). A total of 2 mL of supernatant was 
evaporated to dryness. Finally, the residue was redissolved in 
0.2 mL methanol, following centrifugation at 14,000 × g for 
10 minutes. Following this, 20 µL of the clear supernatant was 
injected into the HPLC system as described above.
Plasma and tissue concentration data obtained were 
pooled to provide mean concentration data. Pharmacokinetic 
parameters in plasma and organs were calculated using 
a statistical moment algorithm and were obtained by 
calculating the area under the concentration-time curve 
(AUC) using the linear trapezoidal rule and extrapolating this 
value to infinity by dividing the last measurable concentration 
by the elimination rate constant.
The anti-inflammatory effect  
of DXMA-NLcs  
on carrageenan-induced rats
An anti-inflammatory test of DXMA-NLCs was performed 
according to the method developed by Lange et al.11 Wistar 
rats were randomly divided into 5 groups (n = 8). Group 1 
(control) received saline; groups 2 and 3 were injected with 
DXMA-NLCs (DXMA equivalent dose of 3 mg/kg or 0.6 mg/
kg); and groups 4 and 5 received DXMA-sol (3 mg/kg or 
0.6 mg/kg). Drugs and saline were given through the tail veins 
1 hour before subcutaneous injection of carrageenan into the 
right hind paws. The paw volume was measured before drug 
administration and then at 0.5, 1, 2, 3, 4, 5, and 6 hours after 
carrageenan injection, using a digital plethysmometer. The 
amount of paw swelling was determined from time to time 
and expressed as follows:
Inhibition ratio% =  (edema  value  of  control 
group − edema value of drug group)/edema value of control 
group × 100%.
hepatoprotective effects  
of DXMA-NLcs on carbon  
tetrachloride-induced mice
Animal treatments
Kunming mice were divided into 8 groups. Group 1 received 
normal saline and served as the control. Animals in groups 2, 
3, 4, 5, 6, and 7 were subcutaneously injected with carbon tet-
rachloride (40% CCl4 in olive oil, 0.2 mL/10 g) on the first day 
and then 0.1 mL/10 g once every 5 days for a period of 4 weeks. 
Group 2 received normal saline and served as a CCl4 intoxica-
tion control (CCl4 group). Group 3 received blank NLC and 
served as the vehicle control. Groups 4 and 5 received DXMA-
sol at doses of 2 mg/kg and 1 mg/kg, respectively. Groups 6, 
7, and 8 received DXMA-NLCs at a DXMA equivalent dose 
of 2 mg/kg, 1 mg/kg, and 0.5 mg/kg, respectively. The normal 
saline and drugs were administered through the tail veins once 
per week over a period of 4 weeks from the second day after 
injection of carbon tetrachloride.
Blood samples were collected from the orbit venous 
plexus 24 hours after the last treatment of drugs and 
were used for biochemical evaluations. The mice were International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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then dissected and the livers were removed for the 
calculation of liver coefficients and then homogenized for 
the determination of hydroxyproline content.
Biochemical evaluations
Liver damage was assessed by estimating serum activities of 
alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), and alkaline phosphatase (ALP) using commercially 
available test kits. The results were expressed as activity 
(IU/100 mL).
Liver coefficients
After weighing the body and liver, the ratio of wet liver 
weight (mg) to total body weight (g) (liver coefficient) was 
calculated.
hydroxyproline content
Hydroxyproline (Hyp) content in liver was determined by the 
Hyp assay kit spectrophotometric method according to the 
manufacturer’s instructions. Data was expressed as Hyp (µg)/
wet liver weight (g).
statistical analysis
Data were expressed as mean and standard deviation (SD) 
and statistically assessed using a one-way analysis of variance 
(ANOVA). Differences between the CCl4 group and the drug 
or NLC-treated groups were evaluated by the Student’s t test, 
with a significance level of P , 0.05.
Results and discussion
Preparation and characterization  
of DXMA-NLcs
DXMA-NLCs were successfully prepared by the film 
dispersion-ultrasonication method using soybean oil 
and egg yolk lecithin as lipid materials with a mean 
particle size of 151 ± 3.5 nm, a PDI of 0.215 ± 0.083, a 
zeta potential of −38.7 ± 3.7 mv, an encapsulation effi-
ciency of 97.11 ± 0.51%, and a drug loading capacity of 
4.41 ± 0.04%. The in vitro release study revealed sustained 
release of drugs from DXMA-NLCs in contrast with the free 
DXMA (Figure 1). While about 100% of the free drug was 
found in release medium after approximately 2 hours, less 
than 10% of the drug released at 1 hour and about 50% of the 
drug released within 12 hours from DXMA-NLCs.
DSC analysis was performed to evaluate possible 
interactions between DXMA and the lipid materials 
(Figure 2). Blank NLCs exhibited 3 melting points at 47°C, 
157.2°C, and 167°C (Figure 2A). Similarly, drug loaded 
NLCs presented melting points at 46.1°C, 157.5°C, and 
167.1°C (Figure 2B). In addition, the typical transitions of 
physical mixture were 49.1°C, 151.5°C, and 166.7°C (Figure 
2C). DXMA alone showed a peak at 233.3°C as seen in Fig. 
2D. No considerable difference could be observed among 
blank NLCs, drug-loaded NLCs, and physical mixture, which 
means the loading of a small amount of drug on NLCs did 
not change the melting points significantly. The DSC ther-
mograms of physical mixture and the drug-loaded NLCs did 
not show a melting peak for DXMA. This absence may be 
induced by the low amount of the drug (4.41 ± 0.04%) in 
DXMA-NLCs, which was coincident with the research of 
Mu et al.12 Their team reported difficulties in detecting the 
endothermic peak of drug in microspheres when the drug 
ratio is lower than 10%.
To further pursue the interaction between the drug and 
lipids,  31P NMR spectral phospholipid profiles of blank 
NLCs, DXMA, DXMA-NLCs, and physical mixtures of 
blank NLCs and DXMA were investigated (Figure 3). The 
spectrum obtained from DXMA indicated there was no 
phosphonium in DXMA. A resonance around 0.40 ppm 
was easily observed in all the spectrum of blank NLCs, 
DXMA-NLCs, and the physical mixture, which was obtained 
from the same P-enriched fraction. This resonance indicated 
there is no significant chemical environmental difference 
of P among blank NLCs, DXMA-NLCs, and the physical 
mixture. Hence, there was no chemical interaction between 
phospholipid and other materials including the drug.
Biodistribution and pharmacokinetics  
in mice
The biodistribution and pharmacokinetics of DXMA-NLCs 
were examined in mice. The percentage of the total 
administered dose (TAD) of free DXMA and NLCs 
in plasma and tissues at different times after iv 
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Table 1 Percentage of TAD of DXMA in plasma and tissues after iv administration of DXMA-NLcs (A) and DXMA-sol (B) in mice
Time (hours) 0.08 0.25 0.5 1 2 4 6 8 10 12
heart A 9.89 12.54 15.67 5.64 4.52 3.06 0.77 0.71 0.00 0.00
heart B 14.46 9.29 6.63 3.39 1.41 1.18 0.00 0.00 0.00 0.00
Liver A 39.10 47.61 55.62 27.55 17.18 7.31 3.31 2.84 4.31 2.21
Liver B 37.35 35.43 34.72 17.91 10.02 2.19 0.00 0.00 0.00 0.00
spleen A 7.94 10.83 10.43 5.36 4.57 0.49 0.44 0.00 0.00 0.00
spleen B 9.86 7.99 5.62 4.93 3.38 0.51 0.00 0.00 0.00 0.00
Lung A 9.96 12.42 9.12 4.29 3.29 0.74 0.00 0.00 0.00 0.00
Lung B 10.21 8.68 9.26 5.46 2.41 1.38 0.00 0.00 0.00 0.00
Kidney A 10.81 5.51 6.29 1.78 1.01 0.91 0.39 0.00 0.00 0.00
Kidney B 11.54 9.70 7.10 1.59 2.00 0.54 0.00 0.00 0.00 0.00
Plasma A 24.19 17.61 13.99 14.88 7.87 1.85 1.14 0.00 0.00 0.00
Plasma B 17.79 18.11 11.58 10.93 8.38 1.40 0.00 0.00 0.00 0.00
Brain A 3.41 2.38 2.38 0.36 0.00 0.00 0.00 0.00 0.00 0.00
Brain B 2.77 3.01 2.88 0.72 0.00 0.00 0.00 0.00 0.00 0.00
administration are summarized in Table 1. The DXMA 
levels after intravenous injection of DXMA-NLCs or 
DXMA solution in various organs are illustrated in 
Figure 4. Different compartment models were used to 
describe the pharmacokinetics of DXMA and DXMA-
NLCs in plasma and tissues. The calculated data were 
closest to observed data when a 2-compartment model was 
applied. The main pharmacokinetic parameters in plasma 
and tissues are shown in Table 2.
The results shown in Figure 4A clearly indicate that 
DXMA-NLCs were preferentially accumulated in the liver. 
The peak concentration of DXMA-NLCs was reached at 0.5 International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 4 DXMA concentrations in plasma and tissues at different time points after i.v. administration of DXMA-NLcs and DXMA-sol.
hours after iv administration and more than 55.62% of TAD% 
was present in the liver, as shown in Table 1. In contrast, the 
peak concentration of free DXMA in the liver occurred at 0.08 
hours as illustrated in Table 1 and Figure 4B and only 2.19% 
of TAD% remained after 4 hours. A 2.57-fold larger area 
under the curve was achieved for DXMA-NLCs compared 
with that of DXMA (Table 2). Meanwhile, DXMA-NLCs 
had an increased t1/2 (1.15 hours) and decreased CL (0.07 
L/h/kg) compared to free DXMA (0.38 hours, 0.17 L/h/kg), 
indicating that NLCs were better retained in the liver than 
free drug. These results clearly indicate a remarkably selec-
tive liver targeting property of DXMA-NLCs, presumably 
because of the general clearance of nanoparticles by the 
phagocytic cells.13 The RES plays a major role in clearing 
small foreign particles from blood, which serves for the 
nanoparticles being passively targeted to certain phagocytic 
cells.13 After intravenous administration with NLCs, they 
were mostly recognized by macrophages (MPS) owing to 
the physicochemical characteristics of   particle size, surface 
charge. and surface hydrophobicity.14,15 An earlier report 
by Reddy indicated that negatively charged SLNs have a 
significantly higher uptake in RES organs, such as the liver 
and spleen.16 Our results for NLCs were in agreement with 
that report. At the same time, because the SLN uptake by 
RES is mediated by particle adsorption of blood proteins 
and opsonins,17 increasing the hydrophobicity of the particles International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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should increase the incidence of adsorption.18,19 Therefore, in 
our study, the lipid matrix, with soybean as the core material 
and lecithin as the surface material, provided hydrophobic 
surfaces of NLCs, leading to enhanced phagocytosis of 
NLCs.20 These results are similar to those observed with 
hydrophobic polystyrene particles, which were intensively 
taken up by cells with phagocytic activity.21–23 Similar liver 
targeting of 9-nitrocamptothecin NLCs has also been dem-
onstrated by Li et al.24
In most reported studies, non stealth SLN formulations 
lead to significantly higher levels of drug remaining in the 
systemic circulation for longer periods of time compared to the 
free drug and this was also the case in our study.7 The AUC of 
DXMA delivered by NLCs in plasma was 1.21-fold higher than 
in corresponding free drug solutions. The half life in plasma of 
DXMA was also increased when administered via NLCs.
Although a study of the anti-Parkinsonian bromocriptine 
NLCs indirectly demonstrated that higher brain levels of bro-
mocriptine were achieved after administration of NLCs,25 a 
higher drug level in the brain was not observed in our study. 
The AUC of NLCs (2.23 µgh/g) was lower than that of the 
free drug (2.72 µgh/g).
The anti-inflammatory effect  
of DXMA-NLcs on carrageenan- 
induced rats
The anti-inflammatory effect of DXMA-NLCs was 
investigated on carrageenan-induced rats. Figure 5 
shows the edema value of DXMA-NLCs and DXMA-sol 
groups, induced by carrageenan, demonstrating that both 
DXMA-NLCs and DXMA-sol were able to prevent edema 
formation compared with the control group (P , 0.05). 
Furthermore, the DXMA-NLCs group exhibited more 
significant responses at lower-dose from 3 to 6 hours 
after carrageenan injection than the DXMA-sol group at 
the same dose (P , 0.05). The percent inhibition value 5 
hours after administration was found to be significantly 
higher for DXMA-NLCs (44.9% ± 1.70%) compared with 
DXMA-sol (14.8% ± 5.5%, P , 0.05). Also, in a study of 
the anti-inflammatory activity of DXMA incorporated into a 
lipid emulsion, the effect of a DXMA emulsion at a low dos-
age was found to be as potent as DXMA sodium phosphate 
at a high dosage.26
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Figure 5 The edema value (cm) of DXMA-NLcs and DXMA-sol on carrageenan induced paw edema in rats.
Table 2 The pharmacokinetic parameters of DXMA-NLcs (A) 
and DXMA-sol (B) in tissues and plasma
Tissues AUC (µg*h/g) T1/2 (h) CL (L/h/kg)
A B A B A B
heart 29.84 13.91 0.71 0.44 0.34 0.72
Liver 152.95 59.48 1.15 0.38 0.07 0.17
spleen 13.44 15.26 0.91 0.45 0.71 0.66
Lung 16.91 17.44 69.31 0.43 0.59 0.57
Kidney 12.42 11.93 0.64 0.35 0.81 0.84
Plasma 41.95 34.78 0.55 0.41 0.24 0.29
Brain 2.23 2.72 0.16 0.16 4.48 3.67International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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hepatoprotective effects  
of DXMA-NLcs on carbon  
tetrachloride-induced mice
Carbon tetrachloride (CCl4) is a classical hepatotoxicant 
that causes rapid liver damage progressing from steatosis 
to centrilobular necrosis. Long term administration of CCl4 
causes chronic liver injury, and the CCl4-induced animal 
model is a widely accepted as producing hepatic fibrosis.27,28 
As shown in Tables 3 and 4, the liver coefficient, contents of 
Hyp, serum levels of AKP, AST, ALT were all significantly 
increased after CCl4 treatment, which together imply the 
successful establishment of the model. The contents of Hyp, 
serum levels of enzymes in the blank NLC group were close 
to that of the CCl4 group, suggesting that blank NLC had no 
obvious impairing effect on the liver. When administered 
with DXMA and DXMA-NLCs, the aforementioned param-
eters were all significantly decreased (P , 0.05). It should 
be stressed that the levels of the liver coefficient and Hyp 
contents of DXMA-NLCs group at the intermediate dose 
(1 mg/kg) were 56.80 mg/g, 0.22 ± 0.39 µg/mg liver, respec-
tively, which were much lower than those of the DXMA-sol 
group (65.25 mg/g, 0.66 ± 0.42 µg/mg liver, P , 0.05) with 
the same dose. Even if no remarkable differences were found 
for high dose groups between DXMA and DXMA-NLCs, 
the protecting effect of DXMA-NLCs at intermediate and 
low dosages was equal to the effect generated by drug solu-
tions at high dosage (2 mg/kg, P . 0.05). All of these results 
may be related to the liver accumulation of NLCs. From 
the aforementioned in vivo biodistribution results, we can 
see a 2.57-fold larger area under the curve, an increased t1/2 
(1.15 hours), and decreased CL (0.07 L/h/kg) were achieved 
by DXMA-NLCs compared with that of DXMA (Table 2). 
Furthermore, contributions from diverse accumulation in the 
liver may be responsible for the different hepatic protection 
effect between DXMA-NLCs and DXMA-sol. In this study, 
DXMA-NLCs with a mean particle size of 151 ± 3.5 nm, a 
zeta potential of −38.7 ± 3.7 mv, and surface hydrophobicity 
may be mainly taken up by reticuloendothelial systems and 
transported into nonparenchymal hepatic cells in liver. Kuffer 
cells, stellate cells, endothelial cells are the members of 
nonparenchymal hepatic cells, which play a pivotal role in 
continuing the inflammation with releasing cytokine. Interfer-
ence with this cytokine release by DXMA could inhibit cells 
factor release and relive hepatic inflammation. However, for 
free DXMA, Melgert et al reported it is always accumulated 
in parenchymal cells which are not the main producers of 
collagens.1 Although further experiments concerning the 
hepotoprotecting effect mechanism of DXMA-NLCs are 
necessary, this hypothesis could explain why DXMA-NLCs 
generally induced lower liver coefficient and Hyp contents 
than DXMA.
It should be stressed the dose-effect relationship prob-
lem also occurred in our research. As shown in Table 3, 
among DXMA and DXMA-NLCs groups, the Hyp content 
(0.43 µg/mg liver) decreased after injection with a high-dose 
of DXMA-sol (2 mg/kg), compared to a low-dose DXMA-sol 
(0.66 µg/mg liver, 1 mg/kg), which was consistent with the 
dose-effect relationship. However, as for DXMA-NLCs, the 
results were different. The highest anti-inflammatory effects 
were achieved with the intermediate dose (1 mg/kg) and 
low dose of DXMA-NLCs (0.5 mg/kg). Liver fibrosis is a 
wound-healing process that is elicited by various toxic stimuli 
and is always associated with inflammation that contributes 
to fibrogenesis.28 It is also characterized by an excessive 
deposition of extracellular matrix (ECM) proteins, in which 
type I collagen predominates.29 Hyp is a specific index 
representing the collagen content of tissues. The inhibition 
of hydroxyproline levels might reduce the availability of 
sufficient hydroxyproline required for collagen synthesis. 
In this study, the lower inhibitory effect caused by the high-
est dose of DXMA-NLCs (2 mg/kg) might be explained by 
the excess concentration of drug. According to the report, 
the anti-inflammatory effect of glucocorticoids involved in 
multiple cytokines and mediators of inflammation may result 
in the complication of the dose-effect relationship.30 Some 
cytokines, such as TNF-α, IFN-γ, and IL-1β, could signifi-
cantly stimulate the ICAM-1 expression in fibroblasts. Dex-
amethasone (DXM) markedly inhibited these stimulations but 
the effective concentrations and time were variable. The effect 
of DXM on TNF-α appeared at the lowest dosage, while 
for IFN-γ, the results were highly correlated with the linear 
Table 3 Liver coefficient and hydroxyproline (Hyp) content of 
ccl4 induced rats after administration of drugs
Group Dose 
(mg/kg)
Liver coefficient 
(mg/g)
Hyp 
(μg/mg liver)
Normal control 53.05 ± 4.94∆∆∆ 0.40 ± 0.23∆∆
ccl4 76.30 ± 12.64 1.23 ± 0.49
Blank-NLc 65.13 ± 9.51∆∆ 1.34 ± 1.11
DXMA sol 2 56.07 ± 4.11∆∆∆ 0.43 ± 0.45∆∆∆
DXMA sol 1 65.25 ± 9.52∆∆ 0.66 ± 0.42∆∆∆
DXMA-NLc 2 60.77 ± 6.53∆∆∆ 0.40 ± 0.30∆∆∆
DXMA-NLc 1 56.80 ± 6.90∆∆∆, # 0.22 ± 0.39∆∆, #
DXMA-NLc 0.5 59.19 ± 4.79∆∆∆ 0.30 ± 0.31∆∆, #
∆∆significant difference from CCl4 group (P , 0.05).
∆∆∆significant difference from CCl4 group (P , 0.001).
#significant difference from DXMA-sol group (1 mg/g) (P , 0.05).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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dose-effect relationship and for IL-1β, the inhibitory effect 
after administration with DXM varied with time. DXM can 
increase the stimulant effect of IL-1β at 24 hours but shows 
an inhibitory effect at 48 hours and there were no signifi-
cant differences among the different concentration groups. 
Another report about dose-related effects of dexamethasone 
on liver damage suggests that high-dose dexamethasone does 
not provide any additional protective effect on liver damage 
compared to the low-dose group.31 Moreover, high-dose 
dexamethasone causes obvious growth retardation. Thus, a 
low dose of corticosteroid provides a significant reduction 
in liver damage without increased side effects, while a 
high dose is associated not with weaker fibrosis but with 
increased side effects. A study of dexamethasone coupled 
with albumin also demonstrated that at low concentrations 
(0.02 µM), Dexa10-HSA was more efficient at inhibiting 
TNF-α production than uncoupled Dexa.1 Therefore, after 
incorporation into NLCs, DXMA also showed a complicated 
dosage-effect relationship.
Another interesting thing was that there were no 
differences for serum levels of AKP, AST, ALT between 
DXMA-sol and DXMA-NLCs groups, which implies that 
the inhibiting effect of DXMA-NLCs on hepatic cirrhosis 
formation may be not directly through protecting liver 
parenchyma cells.32 Further research is being carried out to 
investigate this.
Conclusion
Results gained in the present study indicated that 
DXMA loaded NLCs significantly improved the in 
vitro release, biodistribution, pharmacokinetic, and 
therapeutic properties of DXMA. The NLCs remarkably 
prolonged drug circulation time in plasma and increased 
drug accumulation in the liver. In research of the 
anti-inflammatory effects on carrageenan-induced rats 
and heptoprotective effect on CCl4-induced mice, DXMA-
NLCs exhibited a significant anti-inflammatory and hep-
toprotective effect compared with DXMA-sol. However, 
the effect of DXMA-NLCs was not in proportion to the 
dosage. The intermediate and low dosages presented bet-
ter anti-inflammatory and heptoprotection effects than 
DXMA-sol.
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